Welcome to our dedicated page for Charles Riv Labs Intl news (Ticker: CRL), a resource for investors and traders seeking the latest updates and insights on Charles Riv Labs Intl stock.
Charles River Laboratories International, Inc. provides products and services used in drug discovery, early-stage development, safety assessment, and the manufacture of new therapies. Company news commonly covers results from its Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions activities, along with updates on research models, nonclinical toxicology, microbial and biologics testing, and client demand trends.
Recurring developments also include digital pathology initiatives, AI-enabled workflow tools, rat in vitro fertility services, virtual control groups, and the Alternative Methods Advancement Project™, which relate to efficiency and reduced animal use where scientifically appropriate. Financial releases, investor presentations, governance updates, and portfolio changes are also recurring disclosure themes for CRL.
Charles River Laboratories (NYSE: CRL) will release its second-quarter 2026 financial results on Wednesday, August 5, before the market opens. On the same day at 9:00 a.m. ET, the company will host a conference call, with a live webcast and replay available via the Investor Relations section of its website at ir.criver.com.
Charles River (NYSE: CRL) announced a collaboration with Arovella Therapeutics (ASX: ALA) to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell bank characterization and viral safety testing supporting Arovella’s ALA-101 iNKT cell therapy platform for lymphoma and leukemia.
The U.S. FDA accepted the use of NGS for viral safety testing in Arovella’s IND, validating this approach. Charles River will also perform viral safety release testing on ALA-101 clinical batches and recently strengthened its NGS capabilities through the acquisition of Pathoquest, expanding sequencing-based testing across the biopharmaceutical development pipeline.
Charles River (NYSE: CRL) entered a collaboration with Lilly TuneLab, an AI/ML drug discovery platform created by Eli Lilly. Charles River will provide nonclinical testing services to TuneLab companies, supporting candidate down-selection, protocol standardization, and improved model learning while advancing new approach methodologies (NAMs) through its AMAP initiative.
Charles River Laboratories (NYSE: CRL) will present at two investor conferences. The company is scheduled for the William Blair 46th Annual Growth Stock Conference on June 2 at 10:00 a.m. CT (11:00 a.m. ET), and the Jefferies Global Healthcare Conference on June 3 at 9:55 a.m. ET.
Management will discuss strategic focus, business developments, and recent trends. Live webcasts and two-week replays will be available on the Investor Relations section of the Charles River website at ir.criver.com.
Charles River Laboratories (CRL) and MEDIPOST signed a strategic, non-exclusive MOU to collaborate on GMP-compliant testing and joint commercial and marketing efforts for cell therapies.
The agreement supports MEDIPOST’s global cell therapy pipeline, initially in APAC and North America, leveraging Charles River’s biologics quality control, viral and release testing expertise.
Charles River (NYSE: CRL) announced an AI-enabled, end-to-end digital pathology workflow designed to cut at least one week from standard pathology timelines while maintaining GLP standards and regulatory readiness.
The platform integrates LIMS, AI-powered slide QC, GLP-validated digital primary reviews, and decision-support tools that may boost pathologist efficiency and support 3R-aligned animal reduction through Virtual Control Groups.
Charles River Laboratories (NYSE: CRL) reported Q1 2026 revenue $995.8M, GAAP loss per share $(0.30) and non-GAAP EPS $2.06. The company completed the CDMO and Cell Solutions divestiture on May 6, 2026, repurchased $200M of stock in Q1, and reaffirmed 2026 organic revenue and non-GAAP EPS guidance.
Q1 results reflected a 1.2% reported revenue increase, a GAAP net loss driven by an $118.0M loss on assets held for sale, and lower non-GAAP operating margin vs. prior year.
Charles River (NYSE: CRL) launched commercial rat In Vitro Fertility (IVF) services on April 30, 2026, positioning itself as the first commercial provider for rat-model IVF. The service bundle includes embryo transfer, cryopreservation, rederivation, dedicated project management, optional health monitoring, and genetic validation.
Charles River says the offering aims to shorten breeding timelines, reduce animal use, recover valuable lines, expand cohorts, and maintain VAF/Elite (SOPF) health standards; streamlined quotes and timelines are available starting this quarter.
Charles River (NYSE: CRL) reported a peer-reviewed retrospective analysis showing Virtual Control Groups (VCGs) matched concurrent controls for key outcomes in 20 toxicology studies. The review found 100% concordance in NOAEL and noted up to a 25% reduction in control-animal use where appropriate. The company highlighted ongoing refinement, collaboration via the VICT3R consortium, and an EMA draft qualification step toward broader regulatory acceptance of VCGs.
Charles River Laboratories (NYSE: CRL) will release first-quarter 2026 financial results on Thursday, May 7, 2026, before the market opens. A conference call to discuss results is scheduled the same day at 8:30 a.m. ET. Investors can listen via live webcast at the company's Investor Relations site and access a replay there.